Myeloma Clinical Investigator @DanaFarber @harvardmed via @MoffittNews USF Heme/onc, @NorthwesternU BME, Baker, Jersey girl. Views = my own, not employer
My summary of CARTITUDE4, MajesTEC3, MajesTEC9 and MoumenTAL3. In anti-CD38 refractory patients and EMDs -->TCE anti-BCMA or anti-GPRC5D are >> to Cilta-Cel
History in action here at #EHA2026!
Such impressive PFS & OS with a BCMA-sparing #downwithdex regimen in myeloma... a few of my own patients are on these K-M curves and doing great.
Tal-Dara ± pom (adding pom: more neutropenia/fatigue but ❓ slightly higher PFS) coming soon!
📄1/ Our multicenter real-world study of elranatamab in relapsed/refractory multiple myeloma is out today in @BloodCancerJnl.
The main finding: outcomes in routine practice were meaningfully less favorable than those reported in MagnetisMM-3 cohort A.
https://t.co/nslRx16ywj
Anti-CD70 CAR-NK Cells Overcome BCMA Downregulation and Improve Survival in High-Risk Multiple Myeloma Models. Potential future role in MM relapsing after anti-BCMA Rx #mmsm#bmtsm@MDAndersonNews@lab_rezvani@BCD_AACR https://t.co/3GRLvRA1TZ
We’re thrilled that both our adult and pediatric stem cell/bone marrow transplant programs earned the highest possible +1 score in the 2025 @CIBMTR Survival Report — exceeding expected 1-year survival nationwide. Thank you to our dedicated team and partners for advancing patient care every day. Learn more: https://t.co/BMbN681I8i
How grateful are we in the #myeloma coMMunity to have dedicated and caring specialists spend their Saturday to present to patients and care partners?! @andrew02114@ShoMidha@IMFmyeloma Regional Community Workshop in Waltham, MA #KnowMyeloma
1/ Our call to action is out in @BloodAdvances!
Title speaks for itself. Given concerningly high infection risk with bsAbs in myeloma #MMsm, IVIG/SCIG should be started regardless of any IgG threshold.
Global authors & global audience, including insurance & healthcare funders.
Thanks @VuMedi for featuring our @BloodAdvances piece around driving restrictions following CAR-T therapy in MM.
Driving cars after CARs: an easy Twitter pun but a fundamentally important issue for pts. Data don't support 8-week driving restrictions!
https://t.co/sSDE9jM3tv
#Myeloma Paper of the Day: Single-cell analysis of myeloma TME after gamma-secretase inhibition & CAR T therapy finds reduction in non-classical monocytes & monoallelic BCMA deletion in some pts w/ prior anti-BCMA which correlated w/ reduced PFS: https://t.co/RVnKmnV5m5. #mmsm
New: cilta-cel, a #CART for multiple myeloma, found highly effective in first real-world study.
Read more from @SurbhiSidanaMD and colleagues today in @BloodJournal: https://t.co/suFaGSSOoS #mmsm#Cartitude
#Myeloma Paper of the Day: Pre-clinical in vitro data suggest CD38/CD3xCD28 trispecific T-cell engager (SAR442257) may work in patients after prior daratumumab: https://t.co/ckst0KO7It. Interestingly, TCE lacking CD38-binding also worked, suggesting CD28 binding is enough. #mmsm